The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas-Reference-Cited by-同舟云学术

The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas

Published:2021-07-27 Issue:8 Volume:14 Page:777-787
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Karube Kennosuke¹,Kakimoto Yoshihide²,Tonozuka Yukio²,Ohshima Koichi³

Affiliation:

1. Department of Pathology and Cell Biology, University of the Ryukyus, Okinawa, Japan

2. Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan

3. Department of Pathology, School of Medicine, Kurume University, Kurume, Japan

Funder

Pharmaceutical Co. Ltd.

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2021.1955344

Reference61 articles.

1. JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL)

2. Epidemiology of the non-Hodgkin’s lymphomas: Distributions of the major subtypes differ by geographic locations

3. Peripheral T cell lymphoma in Asia

4. National Comprehensive Cancer Network clinical practice guidelines. T-cell lymphomas version 1.2021 – October 5, 2020. [cited 15 May 2021]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

2. Promising immunotherapeutic approaches for primary effusion lymphoma;Exploration of Targeted Anti-tumor Therapy;2024-06-26

3. Peripheral T‐cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK‐negative;British Journal of Haematology;2024-04-12

4. Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin;Journal of Clinical Medicine;2024-01-31

5. Extracellular CD30 and ADAM10/17 regulate brentuximab vedotin-induced cell death in an adult T-cell leukemia cell line;2023-11-20